Double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg daily or placebo, followed by 8 weeks of open-label mirtazapine 15 mg daily
Double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg or placebo, followed by 8 weeks of open-label mirtazapine Two weeks run-in, 8 weeks randomized, 8 weeks open label Assessments include * dyspepsia questionnaire * Nepean dyspepsia index * Daily diary * Vital signs
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
35
Mirtazapine 15 mg daily
University Hospitals
Leuven, Flanders, Belgium
Difference in dyspepsia symptom scores week 8 versus week 0
The Dyspepsia Symptom Score is calculated from the dyspepsia symptom severity questionnaire at weeks 0, 4 and 8. The symptom score has been used in previous studies (Tack et al., Gastroenterology 1998).
Time frame: Week 8 compared to week 0
Individual symptom severities
Individual symptom scores from the dyspepsia symptom score (DSS) which is used as primary endpoint
Time frame: Week 8 compared to week 0
Nepean dyspepsia index for quality of life in functional dyspepsia
Use of the validated NDI.
Time frame: Week 8 compared to week 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.